Tag: trials

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.

https://link.springer.com/book/10.1007/978-3-031-94113-9

The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.

Continued progress across pipeline programs with focus on pancreatic cancer

– Live video webcast on Thursday, August 21^st at 2:20 PM ET

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH